With the success of these two immunology drugs, AbbVie now anticipates $24.7 billion in combined sales in 2025, raising its previously issued guidance by close to $900 million.

AbbVie (NYSE: ABBV) is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's ...

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow. Jun. 17, 2025 6:42 AM ET AbbVie Inc. (ABBV) ... AbbVie remains very active in immunology, oncology, and neuroscience.

AbbVie also expects, opens new tab peak sales of the drugs to exceed $21 billion in 2027. The two drugs are part of the company's long-term growth strategy to offset Humira's loss of exclusivity.

AbbVie reaps billions of dollars annually from its big-selling immunology medicine Humira, and, under deals with biosimilar makers, the drug is likely free from U.S. competition until 2023.

Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company, we believe the firm's ...

In addition to the financial benefit to Sosei Heptares, the deal will also no doubt help replenish AbbVie’s pipeline in immunology. The drugmaker faces a significant erosion in sales with the ...

RELATED: AbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says The biosim player still needs FDA approval before it can launch its biosim. It also needs to await the ...

AbbVie raises profit forecast despite potential tariffs on demand for new immunology drugs Drugmaker plans to build four new U.S. sites CEO outlines strategies to mitigate tariff impacts April 25 ...

AbbVie is scheduled to report full-year earnings on Jan. 31, but management said at the J.P. Morgan Healthcare Conference last week that the company grew in fiscal year 2024 despite falling sales ...